The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.
Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab ...
In today’s world, consumers expect seamless, engaging experiences at every touchpoint – from discovery to decision. Yet, when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback